Adam B. Weiner, Urologist at Cedars Sinai Medical Center, shared a post on X:
“Big prostate cancer paper in Nature claimed NSD2 inhibition could reverse lineage plasticity + resensitize CRPC/NEPC models to enzalutamide.
Now retracted.
Reason: animal welfare protocol breaches in mouse control arms – tumor burden/bodyweight data confirmed protocol endpoints weren’t followed.
Important nuance: authors state no other experimental data/analyses were affected – but the paper is still retracted.
Translation: promising biology, but the in vivo evidence did not meet standards”
Other articles about GU Oncology on OncoDaily.